InMed sets CVR record date ahead of Mentari merger
Alpha Vantage · The Globe and Mail · · AI-summarised by FinFlash
InMed Pharmaceuticals has set November 5, 2026, as the record date for distributing contingent value rights to shareholders ahead of its proposed merger with Mentari Therapeutics. Holders of record will receive one CVR per common share, contingent on approval of a Return of Capital Proposal at the annual meeting on November 4, 2026.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.